AU2022308705A1 - Semaglutide depot systems and use thereof - Google Patents

Semaglutide depot systems and use thereof Download PDF

Info

Publication number
AU2022308705A1
AU2022308705A1 AU2022308705A AU2022308705A AU2022308705A1 AU 2022308705 A1 AU2022308705 A1 AU 2022308705A1 AU 2022308705 A AU2022308705 A AU 2022308705A AU 2022308705 A AU2022308705 A AU 2022308705A AU 2022308705 A1 AU2022308705 A1 AU 2022308705A1
Authority
AU
Australia
Prior art keywords
semaglutide
long
pharmaceutical composition
parenteral pharmaceutical
acting parenteral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022308705A
Other languages
English (en)
Inventor
Nadav BLEICH KIMELMAN
Ehud Marom
Shai Rubnov
Galina ZATS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mapi Pharma Ltd
Original Assignee
Mapi Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mapi Pharma Ltd filed Critical Mapi Pharma Ltd
Publication of AU2022308705A1 publication Critical patent/AU2022308705A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2022308705A 2021-07-05 2022-07-04 Semaglutide depot systems and use thereof Pending AU2022308705A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163218405P 2021-07-05 2021-07-05
US63/218,405 2021-07-05
US17/534,533 2021-11-24
US17/534,533 US11865213B2 (en) 2021-07-05 2021-11-24 Semaglutide depot systems and use thereof
PCT/IL2022/050708 WO2023281495A1 (en) 2021-07-05 2022-07-04 Semaglutide depot systems and use thereof

Publications (1)

Publication Number Publication Date
AU2022308705A1 true AU2022308705A1 (en) 2024-01-18

Family

ID=84801375

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022308705A Pending AU2022308705A1 (en) 2021-07-05 2022-07-04 Semaglutide depot systems and use thereof

Country Status (8)

Country Link
US (2) US11865213B2 (https=)
EP (1) EP4366759A4 (https=)
JP (1) JP2024526279A (https=)
AU (1) AU2022308705A1 (https=)
CA (1) CA3220567A1 (https=)
IL (1) IL309789A (https=)
MX (1) MX2024000050A (https=)
WO (1) WO2023281495A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025229403A1 (en) * 2024-05-02 2025-11-06 Camurus Ab Lipid compositions and methods of use thereof

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11865213B2 (en) * 2021-07-05 2024-01-09 Mapi Pharma Ltd. Semaglutide depot systems and use thereof
NL2036269B1 (en) 2023-11-14 2025-05-23 Nanomi B V Peptide microparticle compositions and related methods
KR102930984B1 (ko) * 2024-01-29 2026-02-25 주식회사 티온랩테라퓨틱스 세마글루타이드의 개선된 의료 요법 제공을 위한 비만 및 당뇨 치료용로써, 소수성 이온 페어링 겔레이션을 통한 초기 방출이 제어된 데포 조성물 및 이의 제조방법
WO2025165146A1 (ko) * 2024-01-29 2025-08-07 주식회사 티온랩테라퓨틱스 세마글루타이드 또는 티르제파타이드의 개선된 의료 요법 제공을 위한 비만 및 당뇨 치료용으로써, 소수성 이온 페어링 겔레이션을 통한 초기 방출이 제어된 데포 조성물 및 이의 제조방법
CN121015560B (zh) * 2025-10-30 2026-01-30 上海银诺医药技术有限公司 依苏帕格鲁肽α纳米冻干胶束及其制备方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008021531A2 (en) * 2006-08-17 2008-02-21 University Of Massachusetts Stabilized emulsions, methods of preparation, and related reduced fat foods
TWI362947B (en) * 2007-03-08 2012-05-01 Univ Kaohsiung Medical Controlled release pharmaceutical composition and manufacture method thereof
HUE060304T2 (hu) 2010-01-04 2023-02-28 Mapi Pharma Ltd Glatiramer acetátot tartalmazó depó rendszer
EP2866825B1 (en) * 2012-07-01 2020-04-08 Novo Nordisk A/S Use of long-acting glp-1 peptides
BR112016022550B1 (pt) * 2014-03-31 2023-03-28 Pharmathen S.A Processo para a preparação de microesferas de plga de acetato de octreotida
CN105963257B (zh) * 2016-04-26 2021-01-22 广州帝奇医药技术有限公司 一种缓释微粒的制备方法
CN105963258B (zh) * 2016-04-26 2021-01-22 广州帝奇医药技术有限公司 一种缓释微粒的制备方法
CN109982712A (zh) 2016-08-31 2019-07-05 Mapi医药公司 包含醋酸格拉替雷的储库系统
CA3040906A1 (en) * 2016-10-20 2018-04-26 Peptron, Inc. Methods of delivering a neuroprotective polypeptide to the central nervous system
US20190380967A1 (en) 2017-01-23 2019-12-19 Savior Lifetec Corporation Preparation of microparticles of an active ingredient
KR102047983B1 (ko) 2017-11-30 2019-11-22 주식회사 지투지바이오 안전성 및 저장 안정성이 향상된 생분해성 미립구의 제조방법
CN110101846B (zh) 2018-02-01 2022-09-23 齐鲁制药有限公司 一种低突释率的索玛鲁肽微球及其制备方法
US20210162013A1 (en) 2018-08-03 2021-06-03 Brown University Compositions and methods for improving the bioavailability of glp1 and analogues thereof
US20220183964A1 (en) 2019-04-11 2022-06-16 Foundry Therapeutics, Inc. Implantable polymer depots for the controlled, sustained release of therapeutic agents
JP7336813B2 (ja) 2019-07-29 2023-09-01 ペプトロン インコーポレイテッド レボドパ誘発性ジスキネジアの治療または進行抑制用の薬学組成物
CN113018277B (zh) * 2019-12-25 2023-10-31 丽珠医药集团股份有限公司 注射用缓释制剂及其制备方法
CN115484935A (zh) 2020-02-14 2022-12-16 G2G生物公司 包括含有glp-1类似物或其药学上可接受的盐的缓释微球的药物组合物
WO2022003662A1 (en) * 2020-06-29 2022-01-06 Mapi Pharma Ltd. Low burst-release liraglutide depot systems
US11865213B2 (en) * 2021-07-05 2024-01-09 Mapi Pharma Ltd. Semaglutide depot systems and use thereof
AU2023234747A1 (en) * 2022-03-17 2024-09-12 Mapi Pharma Ltd. Depot systems comprising cariprazine or salts thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025229403A1 (en) * 2024-05-02 2025-11-06 Camurus Ab Lipid compositions and methods of use thereof

Also Published As

Publication number Publication date
IL309789A (en) 2024-02-01
JP2024526279A (ja) 2024-07-17
CA3220567A1 (en) 2023-01-12
WO2023281495A1 (en) 2023-01-12
MX2024000050A (es) 2024-03-08
US20240148653A1 (en) 2024-05-09
EP4366759A1 (en) 2024-05-15
US20230014750A1 (en) 2023-01-19
US11865213B2 (en) 2024-01-09
EP4366759A4 (en) 2025-04-09

Similar Documents

Publication Publication Date Title
US11865213B2 (en) Semaglutide depot systems and use thereof
KR102375262B1 (ko) Glp-1 유사체, 또는 이의 약학적으로 허용가능한 염을 포함하는 서방형 미립구를 포함하는 약학적 조성물
US20230256058A1 (en) Low burst-release liraglutide depot systems
AU2005271242B2 (en) Pharmaceutical compositions for controlled release delivery of biologically active compounds
EP2157967B1 (en) Suspension formulations of insulinotropic peptides and uses thereof
CN104248623B (zh) 使用非水性载体的持续释放制剂
IL266254A (en) Rapid establishment and / or termination of administration of a drug in a substantially stable state
AU2005316545A1 (en) Sustained delivery formulations of octreotide compounds
EP3434263B1 (en) Method for preparing sustained release microparticle
US12251380B2 (en) Depot systems comprising cariprazine or salts thereof
KR20240005579A (ko) 세마글루타이드 또는 이의 약학적으로 허용가능한 염을 포함하는 서방성 미립구 제제 및 이의 제조방법
US12514908B2 (en) Semaglutide depot systems and use thereof
CN117615778A (zh) 索玛鲁肽贮库系统及其用途
HK40104236A (zh) 索玛鲁肽贮库系统及其用途
EP4721726A1 (en) Pharmaceutical composition comprising glp-1 receptor agonist, gip/glp-1 receptor agonist and/or glp-1/gip/gcg receptor triple agonist
JP2025511372A (ja) 新規組成物